Phase III study of perioperative pembrolizumab (pembro) plus cystectomy versus cystectomy alone in cisplatin-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC): KEYNOTE-905.

TPS593Background: Pts with MIBC ineligible for neoadjuvant cisplatin-based chemotherapy who only receive the standard radical cystectomy+pelvic lymph node dissection (RC+PLND) have a high rate of r...